Relay Therapeutics announced updated interim clinical data for RLY-2608, showing a median progression-free survival of 9.2 months in patients with advanced breast cancer, and plans to discuss these results in a conference call on December 11, 2024.
AI Assistant
RELAY THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.